Total
0
Shares
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham - The Market Herald
CEO, James Graham
Source: Finance News Network
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals (RCE) has now been granted a Japanese patent for its synthetic anti-infectives Recce 327 (R327) and Recce 529 (R529)
  • The formulations aim to treat lipid-coated viruses — examples of which include coronaviruses, influenza, HIV, hepatitis, and Ross River virus
  • The company's flagship drug, R327, is currently being tested against COVID-19 and has successfully moved to the next stage
  • Japan is the second-largest pharmaceutical company in the world
  • On the market this afternoon, Recce is up 5.07 per cent and is trading for $1.14 per share

Recce Pharmaceuticals (RCE) has received a Japanese patent for its synthetic anti-infectives Recce 327 (R327) and Recce 529 (R529).

The formulations aim to treat lipid-coated viruses — examples of which include coronaviruses, influenza, HIV, hepatitis, and Ross River virus.

Recce's flagship candidate, R327, is currently being tested against SARS-CoV-2, the virus that causes COVID-19. R529 is a new formulation of the anti-viral.

The Japanese patent, dubbed 'Anti-virus Agent and Method for Treatment of Viral Infection', was granted by the Japan Patent Office (JPO) in the world's second-largest pharmaceutical market.

More broadly, there's an increasing demand for medical aid against infections caused by lipid enveloped or coated viruses in Japan, positioning Recce's candidates to meet the growing need.

"Recce’s intellectual property portfolio continues to grow in-line with our business strategy and the unprecedented global infectious disease crisis before us," CEO James Graham said.

"At now 31 granted patents across three wholly-owned patent families, our market-monopolies reinforce our unique opportunity among a significant-range of both bacterial and viral pathogens," he added.

Earlier this month, Recce reported positive anti-COVID results from a trial of its R327 product. The company found the drug showed "encouraging inhibition" against the virus and will now continue to the next stage of testing.

On the market this afternoon, Recce is up 5.07 per cent and is trading for $1.14 per share at 2:37 pm AEDT.

RCE by the numbers
More From The Market Herald
Oventus Medical (ASX:OVN) - Chairman, Sue MacLeman (centre left) - The Market Herald

" Oventus Medical (ASX:OVN) eyes $5M placement to strengthen balance sheet

Sleep apnoea specialist Oventus Medical (OVN) has received firm commitments to undertake a $5 million placement.
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr. Christian Behrenbruch - The Market Herald

" Telix Pharmaceuticals (ASX:TLX) commences prostate cancer clinical trial

Telix Pharmaceuticals (TLX) has been given the green light to commence a phase three clinical trial of its targeted therapy candidate TLX591 in
Bod Australia (ASX:BDA) - CEO, Jo Patterson - The Market Herald

" Bod Australia (ASX:BDA) records highest ever month of MediCabilis sales

Bod Australia (BDA) has recorded its highest-ever month of medicinal cannabis sales, filling 1789 MediCabilis prescriptions in April.
Prescient Therapeutics (PTX) -CEO & Managing Director, Steven Yatomi - The Market Herald

" Prescient Therapeutics (ASX:PTX) signs new research agreement with Peter MacCallum Cancer Centre

Prescient Therapeutics (PTX) has announced a new research program with the Peter MacCallum Cancer Centre to advance its next-generation CAR-T programs.